220 related articles for article (PubMed ID: 27685149)
21. Risk-adapted Treatment for Severe B-Lineage Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation in Children.
Giraldi E; Provenzi M; Conter V; Colledan M; Bolognini S; Foglia C; Sebastiani R; Fiocchi R; Gianatti A; DʼAntiga L; Rambaldi A
Transplantation; 2016 Feb; 100(2):437-45. PubMed ID: 26270449
[TBL] [Abstract][Full Text] [Related]
22. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment.
Chan TS; Hwang YY; Gill H; Au WY; Leung AY; Tse E; Chim CS; Loong F; Kwong YL
Clin Transplant; 2012; 26(5):679-83. PubMed ID: 22324300
[TBL] [Abstract][Full Text] [Related]
23. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
24. EBV and posttransplantation lymphoproliferative disease: what to do?
Zimmermann H; Trappe RU
Hematology Am Soc Hematol Educ Program; 2013; 2013():95-102. PubMed ID: 24319169
[TBL] [Abstract][Full Text] [Related]
25. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
26. Post-transplant lymphoproliferative disorder after paediatric liver transplantation.
Liu Y; Sun LY; Zhu ZJ; Wei L; Qu W; Wang L; Yuan LL; Zeng ZG
Int J Clin Pract; 2021 Apr; 75(4):e13843. PubMed ID: 33222369
[TBL] [Abstract][Full Text] [Related]
27. A retrospective analysis of post-transplant lymphoproliferative disorder following liver transplantation.
Fararjeh FA; Mahmood S; Tachtatzis P; Yallop D; Devereux S; Patten P; Agrawal K; Suddle A; O'Grady J; Heaton N; Marcus R; Kassam S
Eur J Haematol; 2018 Jan; 100(1):98-103. PubMed ID: 29094407
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus associated post-transplant Hodgkin lymphoma in an adult patient after cord blood stem cell transplantation for acute lymphoblastic leukemia.
Okuno K; Horie Y; Kanai K; Kato M; Kuwamoto S; Okazaki T; Hayashi K
J Clin Exp Hematop; 2009 May; 49(1):45-51. PubMed ID: 19474517
[TBL] [Abstract][Full Text] [Related]
29. Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children.
Chiou FK; Beath SV; Wilkie GM; Vickers MA; Morland B; Gupte GL
Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29388302
[TBL] [Abstract][Full Text] [Related]
30. Primary Central Nervous System Hodgkin Lymphoma-Like Posttransplant Lymphoproliferative Disorder.
Hori YS; Nagakita K; Ebisudani Y; Aoi M; Fukuhara T; Shinno Y
World Neurosurg; 2018 Jun; 114():230-234. PubMed ID: 29609086
[TBL] [Abstract][Full Text] [Related]
31. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy.
Zubizarreta PA; Alfaro E; Guitter M; Sanchez La Rosa C; Galluzzo ML; Millán N; Fiandrino F; Felice MS
J Pediatr Hematol Oncol; 2017 Nov; 39(8):602-608. PubMed ID: 28902084
[TBL] [Abstract][Full Text] [Related]
32. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU; Dierickx D; Zimmermann H; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Salles G; Kliem V; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S
J Clin Oncol; 2017 Feb; 35(5):536-543. PubMed ID: 27992268
[TBL] [Abstract][Full Text] [Related]
33. Post-transplant lymphoproliferative disorders after heart or kidney transplantation at a single centre: presentation and response to treatment.
Aversa SM; Stragliotto S; Marino D; Calabrese F; Rigotti P; Marchini F; Gambino A; Feltrin G; Boso C; Canova F; Soldà C; Mazzarotto R; Burra P
Acta Haematol; 2008; 120(1):36-46. PubMed ID: 18797163
[TBL] [Abstract][Full Text] [Related]
34. Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria.
Füreder A; Kropshofer G; Benesch M; Dworzak M; Greil S; Huber WD; Hubmann H; Lawitschka A; Mann G; Michel-Behnke I; Müller-Sacherer T; Pichler H; Simonitsch-Klupp I; Schwinger W; Szepfalusi Z; Crazzolara R; Attarbaschi A;
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1375. PubMed ID: 33755341
[TBL] [Abstract][Full Text] [Related]
35. Stage IV Classical Hodgkin Lymphoma-type Posttransplant Lymphoproliferative Disorder in a Pediatric Liver Transplant Patient: A Case Report and Review of the Literature.
Choi S; Hong KT; Choi JY; Ahn HY; Ko JS; Suh KS; Park SH; Cheon JE; Shin HY; Kang HJ
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e1015-e1019. PubMed ID: 33769384
[TBL] [Abstract][Full Text] [Related]
36. EBV-specific T-cell immunity in pediatric solid organ graft recipients with posttransplantation lymphoproliferative disease.
Wilsdorf N; Eiz-Vesper B; Henke-Gendo C; Diestelhorst J; Oschlies I; Hussein K; Pape L; Baumann U; Tönshoff B; Pohl M; Höcker B; Wingen AM; Klapper W; Kreipe H; Schulz TF; Klein C; Maecker-Kolhoff B
Transplantation; 2013 Jan; 95(1):247-55. PubMed ID: 23222899
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
Meyer SC; Medinger M; Halter JP; Baldomero H; Hirsch HH; Tzankov A; Dirnhofer S; Passweg JR; Tichelli A
Hematology; 2014 Jul; 19(5):280-5. PubMed ID: 24074746
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients.
Schober T; Framke T; Kreipe H; Schulz TF; Großhennig A; Hussein K; Baumann U; Pape L; Schubert S; Wingen AM; Jack T; Koch A; Klein C; Maecker-Kolhoff B
Transplantation; 2013 Jan; 95(1):240-6. PubMed ID: 23222898
[TBL] [Abstract][Full Text] [Related]
39. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
Kinch A; Sundström C; Tufveson G; Glimelius I
Leuk Lymphoma; 2016 Oct; 57(10):2351-8. PubMed ID: 27104753
[TBL] [Abstract][Full Text] [Related]
40. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.
Ghobrial IM; Habermann TM; Maurer MJ; Geyer SM; Ristow KM; Larson TS; Walker RC; Ansell SM; Macon WR; Gores GG; Stegall MD; McGregor CG
J Clin Oncol; 2005 Oct; 23(30):7574-82. PubMed ID: 16186599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]